TETRA BIO-PHARMA WKN: A2ASQ8 ISIN: CA88166Y1007 Kürzel: TBP Forum: Aktien Thema: Hauptdiskussion

https://www.newswire.ca/news-releases/tetra-bio-pharma-announces-positive-initial-clinical-data-from-both-of-its-ongoing-phase-2-clinical-trials-of-qixleef-tm--805517645.html

@fred, Danke für die Info. Wenn das Wörtchen „potential“ nicht gewesen wäre, hätte das noch eine gewisse Bedeutung. Aber: Fazit: Orphan Drugs sind für Patienten mit seltenen Erkrankungen von höchster Bedeutung; für die Firmen stellen sie eine mal größere, in der Regel jedoch eher kleinere Einnahmequelle dar. Zur Abkürzung von Zulassungszeiten, zur Vereinfachung der Zulassung oder zur Erleichterung des Marktzugangs in Deutschland führt der Orphan Drug-Status nicht. Ich hätte gerne mal eine Meldung: Zulassung ist da!

Info zu Orphan Drugs: https://www.vfa.de/de/wirtschaft-politik/artikel-wirtschaft-politik/was-der-orphan-drug-status-fuer-ein-medikament-bedeutet.html

"We’re pleased to share we have received Orphan Drug Designation from the European Medicines Agency, for QIXLEEF™, as a potential treatment for Complex Regional Pain Syndrome, a chronic neuropathic pain condition."

Yup, Hanni 👍

Ich halte mich da dran! Guy wird schon wissen warum er die Burn Rate strafft, sich auf nur zwei Medikamente konzentriert. Wenn die Studien bestätigt werden, than it will be a different Company. Dazu dann das Thema Government funding... die werden schon wissen wo sie stehen! Wenn die Kinischen Tests nicht das versprochen zeigen, ist auch klar was passiert, oder? https://twitter.com/slowwining/status/1457063911388155909?t=tFOp-ngDM6rL_-BcCmezhA&s=19

Scheinen keine guten News zu sein. Deep Dive: It appears that Tetra Bio-Pharma (TSX: TBP) has cold feet when it comes to raising money. The company last night announced that it has cancelled its previously announced at-the-market financing. Originally announced back in May, the financing enabled the company to raise up to $10 million in gross proceeds by directly selling its shares on the open market, with Canaccord acting as sole agent for the process. The company however has elected to terminate the program as of November 11. Justification for the termination was not provided. Even more curiously, despite the announcement in May, and the fallout in its share price in the time since the announcement, the company has reportedly not sold a single share under the program.

Entweder sie benötigen kein Geld 👍oder sie haben keine Käufer gefunden👎

Gute News. Finde ich

https://www.newswire.ca/news-releases/tetra-bio-pharma-inc-announces-termination-of-at-the-market-offering-883268657.html

https://www.newswire.ca/news-releases/tetra-bio-pharma-receives-positive-opinion-for-orphan-drug-designation-for-qixleef-tm-from-the-european-medicines-agency-884149759.html

Ich habe es im MANAGEMENT’S DISCUSSION & ANALYSIS gefunden: While the Company is still committed to its focus on ARDS and sepsis, Tetra has strategically decided to assign its resources to pain and CINV segments. Tetra is still in discussion with several government bodies for funding of its ARDS-003 program. The Company decided not to proceed into clinical trials without this funding and instead dedicate all of its resources to achieving two other key milestones: QIXLEEF™ trials and REDUVO™ marketing approval. The Company is still exploring co-development opportunities with pharma players involved in ophthalmology. There is no guaranty that funding will be provided by any government bodies or that any co-development opportunities will materialize. The Company will provide further updates as they are known. Fokus auf Marktreife, kann man auch positiv sehen.